Peter H. Krammer

Peter Heinrich Krammer (born in 1946) is a German immunologist and one of the directors of The National Center for Tumor Diseases (NCT),[1] as well as the head of the Division Immunogenetics[2] at the German Cancer Research Center (DKFZ) in Heidelberg.

Krammer studied medicine at the University of Freiburg (Germany), in St. Louis (USA) and in Lausanne (Switzerland) and graduated in 1971.

In 1976, he became an associate at the Institute for Immunology and Genetics at the German Cancer Research Center in Heidelberg.

In 2000, he was one of the founders of Apogenix,[4] a spin-out from the German Cancer Research Center which is a clinical stage biopharmaceutical company developing novel therapeutics by targeting the modulation of apoptosis.

Since 2010, he is also one of the directors of The National Center for Tumor Diseases (NCT).